No abstract available.
Electrocardiography* ; Heart Septal Defects, Atrial* ; Hemodynamics*

No abstract available.
Dermatomyositis*

No abstract available.
Animals ; Catalase* ; Glutathione* ; Lung* ; Rats*

Some variables can influence the efficiency of leukocyte removal filter for red cell concentrates. We performed this study to evaluate whether the filtration efficiency for platelet concentrates(PCs) can be influenced by bedside filter(PXL8K, Pall Corporation, USA) used, platelet storage time and transient stopping of platelet agitation, and to measure the amount of cytokines released from donor leukocytes in PCs during the storage time. In addition, we examined the effect of leukocyte reduction by filtration before the storage of PCs on the subsequent generation of cytokines. Any of the above mentioned variables did not make significant differences. From day 1 to day 5, there were significant increases in IL-1 beta (<1 vs. 8.6 pg/mL, p<0.05), IL-8 (<10 vs. 455.3 pg/mL, p<0.05) and TNF-alpha (<4 vs. 16.6 pg/mL, p<0.05) in unflltered PCs, whereas no increased revels of cytokines were found in the cases of prestorage filtration.
Blood Platelets* ; Cytokines ; Dihydroergotamine ; Filtration* ; Humans ; Interleukin-1beta ; Interleukin-8 ; Leukocytes* ; Tissue Donors ; Tumor Necrosis Factor-alpha

No abstract available.

No abstract available.
Budesonide* ; Humans

No abstract available.
Eosinophils* ; Histamine*

To investigate the influence of first six-month mean for serum biochemical markers, albumin, cholesterol, triglyceride, inorganic phosphate, BUN, creatinine, on survival in hemodialysis, we retrospectively analyzed the 57 patients who were monitored from the start of HD for more than 6 months between January 1988 and December 1995. Exclusion criteria were as follows: transfer to CAPD, transplantation or another dialysis center, HD for less than 6 months, non-compliant, death due to malignant disease, accident and self-withdrawal. The patients were divided into two groups according to the demographic characteristics and the median value of first six-month mean for serum biochemical markers. The mean age was 46.7+/-11.7 year, male-to female ratio was 1.6:1, diabetics were 12 (21.1%), and mean follow-up duration was 39.0+/-26.4 months. Among them 30 patients (52.6%) were died. Diabetic patients had significantly lower 1 year (63.6 vs. 88.8%, p<0.05) and 3 year survival rate (19.1 vs. 62.2%, p<0.05) than non-diabetic patients. Low serum albumin(<3.5g/dl), low serum cholesterol(<130mg/dl) and low serum P (<5.0mg/dl) groups were significantly lower 1 and 3 year survival rate than high serum albumin (63.6 vs. 97.0%; 25.5 vs. 74.6%, p<0.05), cholesterol (71.4 vs. 88.0%; 38.1 vs. 60.8%, p<0.05) and p (71.9 vs. 96.3% ; 47.1 vs. 62.9%, p<0.05) groups, respectively. There were no differences in survival rate according to sex, BUN, TG, and creatinine. By Cox's proportional hazard model, low serum albumin(odds ratio 1.98), cholesterol(odds ratio 1.60), and P(odds ratio 2.09) group were independent risk factors for early death. Low serum albumin level at the start of HD maintained during the follow-up period. Cholesterol and P showed similar results. In conclusion, basal serum biochemical markers associated with visceral protein depletion such as low serum albumin, cholesterol and P seem to be early predictors of mortality in hemodialysis patients.
Biomarkers* ; Cholesterol ; Creatinine ; Dialysis ; Female ; Follow-Up Studies ; Humans ; Mortality ; Peritoneal Dialysis, Continuous Ambulatory ; Proportional Hazards Models ; Renal Dialysis* ; Retrospective Studies ; Risk Factors ; Serum Albumin ; Survival Rate ; Triglycerides

Imatinib mesylate is a selective Bcr/Abl kinase inhibitor and an effective anticancer agent for Bcr/Abl-positive chronic myelogenous leukemia. Most patients in chronic phase maintain durable responses; however, many in blast crisis fail to respond, or relapse quickly. Mutations within the BCR/ABL kinase domain are the most commonly identified mechanism associated with relapse. To overcome the imatinib resistance in CML, many investigators have tried to clarify molecular mechanism for imatinib resistance in cells of patients who failed to respond to imatinib. Our aim was to invesitigate underlying mechanism for imatinib resistance in SR-1 cells, which were derived from a CML patient in blast crisis. We detected the new mutation of BCR/ABL, resulting in premature termination and loss of BCR/ABL fusion protein expression, which might be possible mechanism for the resistance to imatinib in SR-1 cells.
Amino Acid Sequence ; Base Sequence ; Cell Line, Tumor ; Drug Resistance, Neoplasm/*genetics ; Fusion Proteins, bcr-abl/chemistry/*genetics ; Humans ; Leukemia, Myeloid/*genetics ; Molecular Sequence Data ; Mutagenesis, Insertional/*genetics ; Nucleotides/genetics ; Piperazines/*pharmacology ; Point Mutation/*genetics ; Pyrimidines/*pharmacology ; Research Support, Non-U.S. Gov't

OBJECTIVE: This study was done to investigate the genetic polymorphism of Aldehyde Dehydrogenase (ALDH) II and Tryptophan Hydroxylase (TPH) and examine effects of socio-demographic, psychological and genetic factors on the alcohol use in freshmen of a university in Korea. METHODS: ALDH II (N=534) and TPH (N=504) genotypes of 551 subjects were analyzed using polymerase chain reaction and restriction fragment length polymorphism method. The severity of alcohol drinking was assessed by average alcohol use per drinking episode and frequency of drinking per month. Characteristics of alcohol related behaviors, socio-demographic information, and motives and expectancies of drinking in the subjects, were assessed by designed questionnaires and selfreport scales. RESULTS: The frequencies of NN, ND, and DD genotype of ALDH II (N=534) were 64.0%, 30.1%, and 5.8%, while those of AA, AC, and CC genotypes of TPH (N=504) were 31.7%, 48.4%, 19.8% respectively. The distribution of ALDH II genotypes was not correlated with that of TPH genotypes. Subjects with D (-) (NN) genotype showed more average alcohol use per drinking episode (chi2 trend=29.42, p=0.001) and higher severity index of alcohol drinking (F=9.36, df=2, p=0.000) compared with those with D (+) (ND or DD) genotypes. Subjects with D (-) genotype showed higher frequency of heavy drinking behavior (chi2 trend=5.25, p=0.022) and blackout episode (chi2 trend=17.84, p=0.001). Socio-demographic, psychological, and genetic factors seemed to contribute to the severity of alcohol drinking in the subjects. CONCLUSIONS: C allele of TPH genotypes is important in determining the severity of drinking in subjects with NN genotype of ALDH II. Social motive, gender, and D allele of ALDH II genotype are contributing factors to determine the severity of drinking in total subjects. D allele of ALDH II genotypes plays an important role in determining the severity and motives of drinking, and other alcoholrelated behaviors.
Alcohol Drinking ; Aldehyde Dehydrogenase* ; Alleles ; Drinking ; Drinking Behavior ; Genotype* ; Korea ; Polymerase Chain Reaction ; Polymorphism, Genetic ; Polymorphism, Restriction Fragment Length ; Psychology* ; Surveys and Questionnaires ; Tryptophan Hydroxylase* ; Tryptophan* ; Weights and Measures